Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (Note: Request metadata listed "Abeona Therapeutics," but the filing text identifies the registrant as Access Pharmaceuticals, Inc.)
Filing Type: Form 10-Q
Period Ended: March 31, 2008
Business Overview: An emerging biopharmaceutical company focused on nanopolymer chemistry technologies. The company holds one FDA-approved product (MuGard for oral mucositis), two products in Phase 2 clinical trials (ProLindac for cancer, Phenylbutyrate), and several pre-clinical candidates. The reporting period includes the acquisition of Somanta Pharmaceuticals, Inc., closed on January 4, 2008.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $38,000 | $0 |
| Net Loss | $(10,595,000) | $(4,127,000) |
| Net Loss Allocable to Common Stockholders | $(12,428,000) | $(4,127,000) |
| Loss Per Share (Basic & Diluted) | $(2.31) | $(1.17) |
| Research & Development Expenses | $9,645,000 | $413,000 |
| General & Administrative Expenses | $889,000 | $1,139,000 |
| Cash and Cash Equivalents (End of Period) | $226,000 | $359,000 |
| Short-Term Investments | $6,163,000 | $6,762,000 |
| Total Liquidity (Cash + Short-Term Investments) | $6,389,000 | N/A |
| Working Capital | $4,139,000 | $6,239,000 (Dec 31, 2007) |
| Long-Term Debt | $5,500,000 | $5,500,000 |
| Accumulated Deficit | $(126,752,000) | $(114,324,000) |
Material Changes vs. Prior Period
- Revenue: Increased from $0 to $38,000, driven by $17,000 in licensing revenue and $21,000 in sponsored research revenue.
- Net Loss: Increased significantly by $6,468,000 (from $4.1M to $10.6M). The loss allocable to common stockholders increased by $8.3M due to preferred stock dividends.
- R&D Expenses: Surged by $9.2M to $9.6M. The primary driver was a one-time non-cash expense of $8.9M for in-process research and development (IPR&D) related to the Somanta acquisition. Other increases included manufacturing costs for the ProLindac trial ($257k) and higher clinical trial costs.
- Interest Expense: Decreased by $2.4M to $108,000, primarily due to the cessation of amortization on convertible notes that were recognized in 2007.
- Preferred Stock Dividends: $1.83M in preferred stock dividends were recorded in Q1 2008 (none in 2007), including $857k attributed to a beneficial conversion feature on new Series A Preferred Stock and $525k accrued dividends.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity
Management expects capital resources to be adequate to fund operations into the second quarter of 2009. The net cash burn rate for the quarter was approximately $1.05 million per month. The company anticipates incurring losses for the next several years and may need to seek additional financing within the next twelve months.
Unusual Items
- Somanta Acquisition: Closed Jan 4, 2008. Resulted in an immediate $8.9M non-cash IPR&D charge. Consideration included ~1.5M shares of common stock and settlement of $1.6M in acquired accounts payable via stock issuance.
- Series A Preferred Stock Issuance: On Feb 4, 2008, the company raised $2.725M (net proceeds $2.44M) via Series A Preferred Stock and warrants. This triggered a beneficial conversion feature expense of $857k.
Risks and Contingencies
- Going Concern: The auditor's report for the prior year expressed significant doubt about the company's ability to continue as a going concern due to history of losses and liquidity position.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties (all financial reporting performed by the CFO).
- Liquidated Damages: The company may be required to pay liquidated damages (1% per month, capped at 10%) to investors if it fails to maintain an effective registration statement for the conversion of Series A Preferred Stock. As of April 24, 2008, the registration statement was not yet effective.
Investor Verification Checklist
- Capital Runway: Verify if the $6.4M in liquidity (cash + short-term investments) is sufficient to cover the stated $1.05M monthly burn rate through Q2 2009 without dilution.
- Registration Statement Status: Confirm the status of the registration statement for Series A Preferred Stock conversion to assess potential liquidated damages liability.
- Internal Control Remediation: Review plans and progress on hiring accounting staff to address the material weakness in financial reporting controls.
- ProLindac Trial: Monitor the start date and progress of the Phase 2 clinical trial for ProLindac, which is a key driver of future R&D spend and potential revenue.
- Preferred Stock Dilution: Assess the impact of the 3,499.86 shares of Series A Preferred Stock (convertible into ~11.7M common shares) on future earnings per share and ownership dilution.